Govermate logoGovermate
Back to opportunities
DocumentClosednews

Wits VIDA globally advances maternal vaccine to protect newborns from GBS Wits VIDA plays central role in global effort to help protect newborns from sepsis due to Group B Streptococcus (GBS). 29 July 2026

University of the WitwatersrandRef: https://www.wits.ac.za/news/latest-news/research-news/2026/-2026-07/wits-vida-globally-advances-maternal-vaccine-to-protect-newborns-from-gbs.html

Official source

Source domain: wits.ac.za

Collected on 29 July 2026

Always confirm details on the official source before acting.

Our copy (archived 29 July 2026)Official source

What this means

This is a news article from the University of the Witwatersrand (Wits) dated 29 July 2026. It reports that researchers from the Wits Vaccines and Infectious Diseases Analytics (Wits VIDA) Research Unit played a leading role in an international Phase 1/2 clinical trial showing the safety and immunogenicity of Pfizer’s investigational maternal Group B Streptococcus (GBS) vaccine candidate (GBS6). The article states the trial results were published in Nature Medicine and that South Africa was the primary recruiting country. It also notes Wits is enrolling in a Phase 3 trial for GBS6 (NCT07160244).

What this document offers

Read out of this document by Govermate's AI, in its own words. Each one quotes the line it came from — confirm on the official source before acting.

clinical trial enrolmentOngoing

Enrolment in Phase 3 trial for GBS6 (NCT07160244)

Wits says it is enrolling in a Phase 3 trial for GBS6 (NCT07160244), an investigational maternal Group B Streptococcus (GBS) vaccine candidate.

Who it is for
People eligible to participate in the Phase 3 trial for GBS6 (NCT07160244)
How to act on it
Join the Phase 3 trial enrolment being conducted by Wits for GBS6 (NCT07160244).
Show the line this came from
Wits is enrolling in a Phase 3 trial for GBS6 (NCT07160244).

Facts

Reference

https://www.wits.ac.za/news/latest-news/research-news/2026/-2026-07/wits-vida-globally-advances-maternal-vaccine-to-protect-newborns-from-gbs.html

Key Takeaways

  • Date: 29 July 2026
  • Source: Wits University (Wits News, Research news)
  • Subject: maternal vaccine against Group B Streptococcus (GBS) to protect newborns
  • Trial phase: international Phase 1/2 clinical trial
  • Vaccine candidate: Pfizer investigational hexavalent GBS conjugate vaccine (GBS6 / GBS6)
  • Publication: Nature Medicine (Madhi SA et al., 2026)
  • Trial findings: generally well tolerated; robust immune responses to six GBS serotypes; efficient transfer of GBS-specific antibodies from mothers to infants
  • Safety outcomes: comparable between vaccine and placebo recipients for mothers and infants
  • Recruitment: South Africa was the primary recruiting country with the majority of participants
  • Disease burden figures cited: ~300,000 serious infections and 100,000 deaths in young infants globally each year
  • WHO priority: vaccine for development to be given during pregnancy
  • Current status: Wits enrolling in Phase 3 trial for GBS6 (NCT07160244)
  • University of the Witwatersrand (Wits)
  • Wits Vaccines and Infectious Diseases Analytics (Wits VIDA) Research Unit
  • Professor Shabir Madhi
  • Pfizer
  • Nature Medicine
  • World Health Organization (WHO)
  • Clinical trial identifier: NCT07160244

Dates

Closing Date

29 July 2026